The chemotherapeutic drug gemcitabine is most often used to treat pancreatic, ovarian and breast cancers. Doctors also found success in the treatment of pleural and peritoneal mesothelioma and certain types of lung cancer, and often use the drug in combination with another chemotherapy drug to treat these forms of cancer.

Gemcitabine Information

  • Other names: Gemzar
  • Manufactured by: Eli Lilly and Company
  • FDA-approved: Yes
  • Used or tested in: Pancreatic cancer, breast cancer, ovarian cancer, lung cancer and mesothelioma cancer.

Most chemotherapeutic drugs work by killing cells with complex chemical reactions. Gemcitabine can slow the growth of pleural mesothelioma by killing cancer cells and interfering with DNA replication.

These drugs target cells that are dividing rapidly, including cancer cells. Unfortunately, the treatment may also affect some healthy cells, including cells that are involved in hair growth and immunity. This is why many chemotherapy patients lose hair and become easily susceptible to illness.

Gemcitabine was discovered and developed by scientists at the pharmaceutical company Eli Lilly. Gemzar is the registered name of gemcitabine for injection. Mesothelioma patients who do not respond well to platinum-based chemotherapy drugs like cisplatin or carboplatin may do well on gemcitabine instead.

Treatment for Mesothelioma

Get the Best Treatment

Get help connecting with the nation's top mesothelioma doctors and cancer centers.

Get Help Now

Gemcitabine chemotherapy is most often performed on an outpatient basis and is administered intravenously. Treatment typically involves a trip to a doctor's office, clinic or hospital. The procedure usually takes a few hours, with the actual administration of the drug lasting around 30 minutes. In most cases, it is administered once a week for up to seven weeks, though the length of treatment and strength of dosage will depend on the type and stage of cancer.

The drug may be administered alone or in combination with another chemotherapy drug. It may be used in first-line or second-line chemotherapy regimens for mesothelioma. First-line chemotherapy with gemcitabine is most often given in combination with another chemotherapy drug, such as cisplatin. Second-line chemotherapy with this drug may be administered alone or in combination, depending on the patient and how they responded to first-line chemotherapy.

When considering treatment with gemcitabine, it is necessary for patients to inform their doctor of current medications being taken, including all prescription drugs and any vitamins, supplements or over-the-counter medications. In addition, anyone who has impaired liver or kidney function is generally not advised to use gemcitabine, as the drug can cause severe liver and kidney damage. Since gemcitabine and most chemotherapy drugs are known to be harmful to unborn babies, women who are pregnant or breastfeeding should not use this drug.

Side Effects

Side effects of treatment can include the following:

  • Nausea and vomiting
  • Tendency to bruise or bleed easily
  • Constipation or diarrhea
  • Swelling in the ankles, feet, or hands (edema)
  • Less frequent urination
  • Blood in urine, or particularly dark urine
  • Change in kidney function
  • Change in liver function
  • Chest pain
  • Numbness or weakness, most often on one side of the body

  • Confusion, balance impairment, or impaired vision or speech

  • Fever, chills, aching body (similar to symptoms of flu)

  • Sores or white patches inside the mouth

  • Pain or swelling at the location where gemcitabine was administered

Those who are treated with chemotherapy drugs have reduced immune system function since the drug kills certain immune cells. If you are taking gemcitabine for mesothelioma, it's important to avoid contact with people who have colds or other infections. A medical face mask may be worn to protect you from contact with germs.


Several Phase II clinical trials have investigated gemcitabine's effectiveness on mesothelioma. Some Phase II trials report higher response rates or higher overall survival rates than other trials report. Despite inconsistency in results, the general consensus is that the drug can benefit people with mesothelioma.

In 2002, an Australian Phase II clinical trial evaluated the combination of gemcitabine and cisplatin as first-line chemotherapy for pleural mesothelioma. Researchers reported a partial response (meaning the tumor shrank to some degree) in 33 percent of participants. The tumor was stabilized (meaning no tumor growth) in 60 percent of participants. Only 8 percent of participants had progressive tumor development while on the treatment. Participants reported improved quality of life following recovery from treatment and improved respiratory function.

Have a Question About Gemcitabine?

Our team of Patient Advocates are available to answer questions and can even help you find an experienced attorney.

In 2012, results were published from a Phase II clinical trial led by mesothelioma expert Dr. Hedy Kindler on the combination of gemcitabine, cisplatin and the anti-angiogenesis drug bevacizumab. Anti-angiogenesis drugs block the formation of new blood vessels, which is the pathway through which tumors spread cancerous cells in the body. The addition of bevacizumab improved progression-free survival and overall survival in participants with lower pretreatment VEGF levels, but was not significant enough among all participants to warrant further study. However, evidence suggests that combining bevacizumab with pemetrexed could be more effective; a French Phase II/III clinical trial is evaluating the combination and the preliminary results are promising in terms of extending survival rate.

In 2013, a preclinical study performed in mice found benefit in the combination of gemcitabine, vitamin C and EGCG (epigallocatechin-3-gallate, a green tea polyphenol). The combination effectively reduced tumor growth and invasiveness in mice with peritoneal mesothelioma. The addition of vitamin C and EGCG to a lower dose of gemcitabine produced a survival increase that was identical to survival with a higher dose of gemcitabine. These results indicate that the addition of nutritional compounds may increase the effectiveness of gemcitabine at lower doses, which could diminish side effects.

Studies continue to investigate the best ways to administer gemcitabine for the treatment of mesothelioma. The drug's effectiveness may be improved with the addition of other chemotherapy drugs, targeted therapies and nutrition, and trials are ongoing to improve the outcomes of people treated with the drug. People facing mesothelioma who undergo treatment with this drug may experience a reduction of symptoms, improved quality of life and extended survival.

Additional Resources

Support Group for Patients Join the Group Now
Qualify For Free Medical Care Get Help Now
Get Help Paying for Treatment & More Learn More

Karen Selby joined in 2009. She is a registered nurse with a background in oncology and thoracic surgery and was the director of a tissue bank before becoming a Patient Advocate at The Mesothelioma Center. Karen has assisted surgeons with thoracic surgeries such as lung resections, lung transplants, pneumonectomies, pleurectomies and wedge resections.

  1. ASCO University. (2010). IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. Retrieved from
  2. Eli Lilly. (2013, Nov. 19). Gemzar. Retrieved from
  3. Kindler, H.L., Karrison, T.G., Gandara, D.R., Lu, C., Krug, L.M., Stevenson, J.P., … Vokes, E.E. (2012). Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. Journal of Clinical Oncology, 30(20): 2509-2515. doi: 10.1200/JCO.2011.41.5869
  4. Kindler, H.L. & Meerbeeck, J.P. (2002). The role of gemcitabine in the treatment of malignant mesothelioma. Seminars in Oncology, 29(1): 70-76. Retrieved from
  5. Simon, G.R., Verschraegen, C.F., Janne, P.A., Langer, P.A.,Dowlati, A., Gadgeel, S.M., … Kindler, H.L. (2008). Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. Journal of Clinical Oncology, 26(21): 3567-3572. doi: 10.1200/JCO.2007.15.2868
  6. Nowak, A.K., Byrne, M.J., Williamson, R., Ryan, G., Segal, A., Fielding, D., … & Robinson, B.W.S. (2002). A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. British Journal of Cancer, 87(5): 491-496. doi: 10.1038/sj.bjc.6600505
  7. Volta, V., Ranzato, E., Martinotti, S., Gallo, S., Russo, M.V., Mutti, L., … & Burlando, B. (2013). Preclinical demonstration of synergistic active nutrients/drug (AND) combination as a potential treatment for malignant pleural mesothelioma. PLoS One, 8(3): e58051. doi: 10.1371/journal.pone.0058051

Share Our Page

View our resources for patients and families

Get Help Today
Get Your Free Mesothelioma Guide